Intravenous Magnesium Sulphate in Acute Ischemic Stroke

• Status: Not yet recruiting
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Magnesium has a neuroprotective role so the investigators aim to evaluate the role of intravenous magnesium sulphate in improving the clinical outcomes as assessed by the NIH Stroke Scale (NIHSS) in patients with acute ischemic stroke.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dow University of Health Sciences
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Adults with a confirmed diagnosis of ischemic stroke on neurological examination and CT scan findings aged between 45 -95 years of age of either gender.

• Adults presenting within a stroke onset of 24 hours.

Exclusion Criteria:

• Patients with confirmed diagnosis other than ischemic stroke (evidence of Intracranial bleed or space occupying lesion)

• Subjects with systolic blood pressure less than 90mmHg

• Presence of Bundle Branch block or atrioventricular block.

• Serum Creatinine > 3mg/dl

• Respiratory failure (O2 saturation <90% or Respiratory Rate >24 or <12)

• Pregnancy.